{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:39:42Z","timestamp":1761485982372},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Decade of Vaccines Consultancy"},{"name":"World Health Organization's Initiative for Vaccine Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.vaccine.2012.09.045","type":"journal-article","created":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T12:41:49Z","timestamp":1366202509000},"page":"B216-B222","source":"Crossref","is-referenced-by-count":78,"special_numbering":"S2","title":["Group A streptococcal vaccines: Paving a path for accelerated development"],"prefix":"10.1016","volume":"31","author":[{"given":"James B.","family":"Dale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent A.","family":"Fischetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan R.","family":"Carapetis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew C.","family":"Steer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samba","family":"Sow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bongani M.","family":"Mayosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran A.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Mulholland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim Maria","family":"Hombach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Sch\u00f6del","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Maria","family":"Henao-Restrepo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.vaccine.2012.09.045_bib0005","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(05)70267-X","article-title":"The global burden of group A streptococcal diseases","volume":"5","author":"Carapetis","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2012.09.045_bib0010","series-title":"Rheumatic Fever","first-page":"485","article-title":"Cost-effectiveness analysis of intervention strategies for reduction of the burden of rheumatic heart disease","author":"Michaud","year":"1999"},{"issue":"9","key":"10.1016\/j.vaccine.2012.09.045_bib0015","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2165\/11634180-000000000-00000","article-title":"Invasive group a streptococcal disease: epidemiology, pathogenesis and management","volume":"72","author":"Steer","year":"2012","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.vaccine.2012.09.045_bib0020","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa065085","article-title":"Prevalence of rheumatic heart disease detected by echocardiographic screening","volume":"357","author":"Marijon","year":"2007","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.vaccine.2012.09.045_bib0025","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.amjcard.2010.01.364","article-title":"Prevalence of rheumatic heart disease in children and young adults in Nicaragua","volume":"105","author":"Paar","year":"2010","journal-title":"Am J Card"},{"issue":"25","key":"10.1016\/j.vaccine.2012.09.045_bib0030","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1161\/CIRCULATIONAHA.112.092312","article-title":"Echocardiography screening for rheumatic heart disease in Ugandan schoolchildren","volume":"125","author":"Beaton","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2012.09.045_bib0035","unstructured":"Standardized protocols for GAS burden estimation. Available from: http:\/\/www.niaid.nih.gov\/TOPICS\/STREPTOCOCCAL\/Pages\/protocols.aspx [cited 05.09.2012]."},{"issue":"5","key":"10.1016\/j.vaccine.2012.09.045_bib0040","first-page":"297","article-title":"World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease\u2014an evidence-based guideline","volume":"9","author":"Remenyi","year":"2012","journal-title":"Nat Rev"},{"issue":"8","key":"10.1016\/j.vaccine.2012.09.045_bib0045","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1161\/CIRCULATIONAHA.109.849190","article-title":"Rheumatic heart disease screening by echocardiography: the inadequacy of world health organization criteria for optimizing the diagnosis of subclinical disease","volume":"120","author":"Marijon","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.vaccine.2012.09.045_bib0050","unstructured":"CDC Streptococcus Laboratory. Available from: http:\/\/www.cdc.gov\/ncidod\/biotech\/strep\/strepindex.htm [cited 05.09.2012]."},{"key":"10.1016\/j.vaccine.2012.09.045_bib0055","unstructured":"Hilleman Laboratories meeting summary: is a group A streptococcal vaccine desirable and feasible, New Delhi, March 2010. Available from: http:\/\/www.hillemanlabs.org\/pdf\/gas-meeting-summary.pdf; 2011 [cited 05.06.2012]."},{"key":"10.1016\/j.vaccine.2012.09.045_bib0060","unstructured":"Proceedings of the tenth global vaccine research forum and parallel satellite symposia, Geneva, 26\u201329 June 2011. Available from: http:\/\/www.who.int\/immunization\/documents\/innovation\/WHO_IVB_12.06\/en\/index.html; 2012 [cited 25.05.2012]."},{"issue":"8","key":"10.1016\/j.vaccine.2012.09.045_bib0065","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/01.inf.0000136296.98686.c5","article-title":"Progress in group A streptococcal vaccine development","volume":"23","author":"Kotloff","year":"2004","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.vaccine.2012.09.045_bib0070","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1128\/AEM.16.3.509-518.1968","article-title":"Secondary and apparent primary antibody responses after group A streptococcal vaccination of 21 children","volume":"16","author":"Massell","year":"1968","journal-title":"Appl Microbiol"},{"issue":"6","key":"10.1016\/j.vaccine.2012.09.045_bib0075","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/jama.1969.03150190037007","article-title":"Rheumatic fever following streptococcal vaccination. Report of three cases","volume":"207","author":"Massell","year":"1969","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.vaccine.2012.09.045_bib0080","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jama.292.6.709","article-title":"Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial","volume":"292","author":"Kotloff","year":"2004","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.vaccine.2012.09.045_bib0085","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1086\/444458","article-title":"Safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adult volunteers","volume":"41","author":"McNeil","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2012.09.045_bib0090","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ics.2005.12.002","article-title":"A double-blind, randomized, phase II trial of the safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adults","volume":"1289","author":"McNeil","year":"2005","journal-title":"Int Congr Ser"},{"issue":"46","key":"10.1016\/j.vaccine.2012.09.045_bib0095","doi-asserted-by":"crossref","first-page":"8175","DOI":"10.1016\/j.vaccine.2011.09.005","article-title":"New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci","volume":"29","author":"Dale","year":"2011","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2012.09.045_bib0100","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1086\/521264","article-title":"The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000\u20132004","volume":"45","author":"O\u2019Loughlin","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2012.09.045_bib0105","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1128\/JCM.02155-08","article-title":"Clinical and microbiological characteristics of severe Streptococcus pyogenes disease in Europe","volume":"47","author":"Luca-Harari","year":"2009","journal-title":"J Clin Microbiol"},{"issue":"7","key":"10.1016\/j.vaccine.2012.09.045_bib0110","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1128\/JCM.00422-08","article-title":"Epidemiology of severe Streptococcus pyogenes disease in Europe","volume":"46","author":"Lamagni","year":"2008","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2012.09.045_bib0115","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-3156.2010.02670.x","article-title":"Systematic review: estimation of global burden of non-suppurative sequelae of upper respiratory tract infection: rheumatic fever and post-streptococcal glomerulonephritis","volume":"16","author":"Jackson","year":"2011","journal-title":"Trop Med Int Health"},{"issue":"10","key":"10.1016\/j.vaccine.2012.09.045_bib0120","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/ki.2011.478","article-title":"Post-streptococcal glomerulonephritis is a strong risk factor for chronic kidney disease in later life","volume":"81","author":"Hoy","year":"2012","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.vaccine.2012.09.045_bib0125","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1473-3099(09)70178-1","article-title":"Global emm type distribution of group A streptococci: systematic review and implications for vaccine development","volume":"9","author":"Steer","year":"2009","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2012.09.045_bib0130","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1086\/315842","article-title":"Contrasting molecular epidemiology of group A streptococci causing tropical and nontropical infections of the skin and throat","volume":"182","author":"Bessen","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2012.09.045_bib0135","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1128\/IAI.70.4.2171-2177.2002","article-title":"Immunogenicity of a 26-valent group A streptococcal vaccine","volume":"70","author":"Hu","year":"2002","journal-title":"Infect Immun"},{"issue":"46","key":"10.1016\/j.vaccine.2012.09.045_bib0140","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1016\/j.vaccine.2008.08.037","article-title":"Genetic diversity of group A streptococcus M protein: implications for typing and vaccine development","volume":"26","author":"Smeesters","year":"2008","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2012.09.045_bib0145","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1128\/JCM.00312-09","article-title":"emm and C-repeat region molecular typing of beta-hemolytic streptococci in a tropical country: implications for vaccine development","volume":"47","author":"Steer","year":"2009","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2012.09.045_bib0150","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1086\/599344","article-title":"Seven-year surveillance of North American pediatric group a streptococcal pharyngitis isolates","volume":"49","author":"Shulman","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2012.09.045_bib0155","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1128\/IAI.56.10.2666-2672.1988","article-title":"Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci","volume":"56","author":"Bessen","year":"1988","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2012.09.045_bib0160","doi-asserted-by":"crossref","first-page":"888","DOI":"10.4049\/jimmunol.148.3.888","article-title":"Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses","volume":"148","author":"Bronze","year":"1992","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2012.09.045_bib0165","first-page":"104","article-title":"Preclinical evaluation of a vaccine based on conserved region of M protein that prevents group A streptococcal infection","volume":"119Suppl","author":"Batzloff","year":"2004","journal-title":"Indian J Med Res"},{"issue":"10","key":"10.1016\/j.vaccine.2012.09.045_bib0170","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1086\/374800","article-title":"Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection","volume":"187","author":"Batzloff","year":"2003","journal-title":"J Infect Dis"},{"issue":"31","key":"10.1016\/j.vaccine.2012.09.045_bib0175","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1016\/j.vaccine.2010.05.018","article-title":"Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes","volume":"28","author":"Penfound","year":"2010","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2012.09.045_bib0180","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/0974-2069.79616","article-title":"Global research priorities in rheumatic fever and rheumatic heart disease","volume":"4","author":"Carapetis","year":"2011","journal-title":"Ann Pediat Cardiol"},{"issue":"5","key":"10.1016\/j.vaccine.2012.09.045_bib0185","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1128\/JB.01132-06","article-title":"Proteomic analysis and identification of Streptococcus pyogenes surface-associated proteins","volume":"189","author":"Severin","year":"2007","journal-title":"J Bacteriol"},{"issue":"2","key":"10.1016\/j.vaccine.2012.09.045_bib0190","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nbt1179","article-title":"Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome","volume":"24","author":"Rodriguez-Ortega","year":"2006","journal-title":"Nat Biotechnol"},{"issue":"9","key":"10.1016\/j.vaccine.2012.09.045_bib0195","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1128\/IAI.00295-10","article-title":"Novel conserved group A streptococcal proteins identified by the antigenome technology as vaccine candidates for a non-M protein-based vaccine","volume":"78","author":"Fritzer","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2012.09.045_bib0200","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1128\/IAI.60.12.5219-5223.1992","article-title":"Streptococcal C5a peptidase is a highly specific endopeptidase","volume":"60","author":"Cleary","year":"1992","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2012.09.045_bib0205","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1128\/IAI.60.6.2147-2152.1992","article-title":"Multiple adhesins of streptococci","volume":"60","author":"Hasty","year":"1992","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2012.09.045_bib0210","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/INF.0b013e318194b2af","article-title":"Prospective surveillance of streptococcal sore throat in a tropical country","volume":"28","author":"Steer","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"10.1016\/j.vaccine.2012.09.045_bib0215","doi-asserted-by":"crossref","first-page":"7342","DOI":"10.1128\/IAI.72.12.7342-7345.2004","article-title":"Intranasal vaccination with streptococcal fibronectin binding protein Sfb1 fails to prevent growth and dissemination of Streptococcus pyogenes in a murine skin infection model","volume":"72","author":"McArthur","year":"2004","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2012.09.045_bib0220","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/01.qco.0000216623.82950.11","article-title":"Group A streptococcal infections of the skin: molecular advances but limited therapeutic progress","volume":"19","author":"Currie","year":"2006","journal-title":"Curr Opin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2012.09.045_bib0225","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/QCO.0b013e3283511d27","article-title":"Streptococcal skin infection and rheumatic heart disease","volume":"25","author":"Parks","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.vaccine.2012.09.045_bib0230","unstructured":"Sixty-fifth World Health Assembly. Available from: http:\/\/www.who.int\/mediacentre\/events\/2012\/wha65\/en\/index.html [cited 05.09.2012]."},{"issue":"4","key":"10.1016\/j.vaccine.2012.09.045_bib0235","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ymeth.2009.03.024","article-title":"A vaccine against S. pyogenes: design and experimental immune response","volume":"49","author":"Guilherme","year":"2009","journal-title":"Methods"},{"issue":"12","key":"10.1016\/j.vaccine.2012.09.045_bib0240","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.vaccine.2011.12.115","article-title":"Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein","volume":"30","author":"Bauer","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2012.09.045_bib0245","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1086\/498618","article-title":"Group A streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection","volume":"193","author":"Sabharwal","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2012.09.045_bib0250","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1172\/JCI5118","article-title":"New protective antigen of group A streptococci","volume":"103","author":"Dale","year":"1999","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.vaccine.2012.09.045_bib0255","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1086\/377700","article-title":"Immune response to group A streptococcal C5a peptidase in children: implications for vaccine development","volume":"188","author":"Shet","year":"2003","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2012.09.045_bib0260","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1128\/IAI.69.2.924-930.2001","article-title":"Systemic and mucosal immunizations with fibronectin-binding protein FBP54 induce protective immune responses against Streptococcus pyogenes challenge in mice","volume":"69","author":"Kawabata","year":"2001","journal-title":"Infect Immun"},{"issue":"9","key":"10.1016\/j.vaccine.2012.09.045_bib0265","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1128\/IAI.71.9.5097-5103.2003","article-title":"Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci","volume":"71","author":"Courtney","year":"2003","journal-title":"Infect Immun"},{"issue":"9","key":"10.1016\/j.vaccine.2012.09.045_bib0270","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.vaccine.2005.06.039","article-title":"Intranasal immunization with serum opacity factor (SOF) of Streptococcus pyogenes fails to protect mice against lethal mucosal challenge with a heterologous strain","volume":"24","author":"Schulze","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.09.045_bib0275","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1006\/mpat.1994.1044","article-title":"Vaccination with streptococcal extracellular cysteine protease (interleukin 1B convertase) protects mice against challenge with heterologous group A streptococci","volume":"16","author":"Kapur","year":"1994","journal-title":"Microb Pathogen"},{"issue":"4","key":"10.1016\/j.vaccine.2012.09.045_bib0280","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.4049\/jimmunol.165.4.2306","article-title":"Development of streptococcal pyrogenic exotoxin C vaccine toxoids that are protective in the rabbit model of toxic shock syndrome","volume":"165","author":"McCormick","year":"2000","journal-title":"J Immunol"},{"issue":"Pt 4","key":"10.1016\/j.vaccine.2012.09.045_bib0285","first-page":"442","article-title":"Typing of the pilus-protein-encoding FCT region and biofilm formation as novel parameters in epidemiological investigations of Streptococcus pyogenes isolates from various infection sites","volume":"59","author":"Koller","year":"2011","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.vaccine.2012.09.045_bib0290","doi-asserted-by":"crossref","DOI":"10.1096\/fj.09-145631","article-title":"Streptococcus pyogenes SpyCEP: a chemokine-inactivating protease with unique structural and biochemical features","author":"Zingaretti","year":"2010","journal-title":"FASEB J"},{"issue":"7","key":"10.1016\/j.vaccine.2012.09.045_bib0295","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1128\/IAI.00038-07","article-title":"Active and passive immunizations with the streptococcal esterase Sse protect mice against subcutaneous infection with group A streptococci","volume":"75","author":"Liu","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2012.09.045_bib0300","unstructured":"Grandi G, Telford JL, Bensi G, inventors; Novartis Vaccines and Diagnostics, SRL, assignee. Immunogenic compositions for Streptococcus pyogenes. US. 2010."},{"issue":"21\u201322","key":"10.1016\/j.vaccine.2012.09.045_bib0305","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/j.vaccine.2004.01.043","article-title":"Identification and assessment of new vaccine candidates for group A streptococcal infections","volume":"22","author":"McMillan","year":"2004","journal-title":"Vaccine"},{"issue":"Suppl.","key":"10.1016\/j.vaccine.2012.09.045_bib0310","first-page":"121","article-title":"Prospecting for new group A streptococcal vaccine candidates","volume":"119","author":"McMillan","year":"2004","journal-title":"Indian J Med Res"},{"issue":"1","key":"10.1016\/j.vaccine.2012.09.045_bib0315","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/380491","article-title":"Identification of new candidate vaccine antigens made by Streptococcus pyogenes: purification and characterization of 16 putative extracellular lipoproteins","volume":"189","author":"Lei","year":"2004","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2012.09.045_bib0320","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1128\/IAI.73.4.2360-2366.2005","article-title":"Clinical and microbiological responses of volunteers to combined intranasal and oral inoculation with a Streptococcus gordonii carrier strain intended for future use as a group A streptococcus vaccine","volume":"73","author":"Kotloff","year":"2005","journal-title":"Infect Immun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12013655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12013655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T03:54:08Z","timestamp":1688183648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12013655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":64,"alternative-id":["S0264410X12013655"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.09.045","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}